BioSpace News Archive

Policy

Shrader and Associates LLP: Ploetz Lawyers Respond to NCAA

The following is a statement from Justin Shrader, Shrader and Associates LLP:

June 18, 2018
·
1 min read
Biotech Bay

TriStar Centennial Medical Center Acquires the First Levó Head Positioning System by Mizuho OSI

Technology Allows for Better Patient Safety Using Precise and Controlled Motion

June 18, 2018
·
4 min read
Business

North Shore InnoVentures Board Appoints Chris Ilsley as CEO

North Shore InnoVentures announced that its board of directors has appointed Chris Ilsley to CEO and President.

June 18, 2018
·
3 min read
Biotech Beach

Embodied Raises $22 Million in Series A

Joining the board of directors will be Jason Schoettler from Calibrate Ventures and Andrew Firlik from JAZZ Venture Partners.

June 18, 2018
·
2 min read
Drug Development

Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy

Cellerant Therapeutics, Inc. presented results from its randomized controlled Phase 2 clinical trial of CLT-008 (romyelocel-L, human myeloid progenitor cells), an off-the-shelf cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia.

June 18, 2018
·
3 min read
Pharm Country

Blink Health Announces Price Match Guarantee on Nearly All Generic Rx Medications

Blink Health Takes Aim at America’s High Prescription Drug Price Crisis

June 18, 2018
·
4 min read
Biotech Bay

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018

Presentations Will Highlight Use of Tempo Lead as New Standard of Care in Temporary Pacing That Results in Earlier Ambulation and Reduced Length of Stay

June 18, 2018
·
3 min read
BioMidwest

MGIS Launches New High-Limit Disability Insurance Product for Physicians

Company broadens Existing physician income-replacement solutions

June 18, 2018
·
2 min read
Drug Development

Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML).

June 18, 2018
·
3 min read
Drug Development

Scientists Learn More about How Gene Linked to Autism Affects Brain

Study Suggests Modulating CHD8 Might Help Some People with Complex Condition

June 18, 2018
·
3 min read